Invention Grant
US07098015B2 27875, 22025, 27420, 17906, 16319, 55092 and 10218 molecules and uses therefor
有权
27875,22025,27420,17906,16319,55092和10218分子及其用途
- Patent Title: 27875, 22025, 27420, 17906, 16319, 55092 and 10218 molecules and uses therefor
- Patent Title (中): 27875,22025,27420,17906,16319,55092和10218分子及其用途
-
Application No.: US10386414Application Date: 2003-03-11
-
Publication No.: US07098015B2Publication Date: 2006-08-29
- Inventor: Kyle J. MacBeth , Joseph M. Carroll , William James Cook , Rachel E. Meyers , Miyoung Chun , Mark J. Williamson
- Applicant: Kyle J. MacBeth , Joseph M. Carroll , William James Cook , Rachel E. Meyers , Miyoung Chun , Mark J. Williamson
- Applicant Address: US MA Cambridge
- Assignee: Millennium Pharmaceuticals, Inc.
- Current Assignee: Millennium Pharmaceuticals, Inc.
- Current Assignee Address: US MA Cambridge
- Agency: Millennium Pharmaceuticals Inc.
- Main IPC: C12N9/16
- IPC: C12N9/16 ; C12N15/54 ; C12N15/62 ; C12N15/79
Abstract:
The invention provides isolated nucleic acids molecules, designated 27875, 22025, 27420, 16319, 55092 and 10218 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27875, 22025, 27420, 16319, 55092 and 10218 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 27875, 22025, 27420, 16319, 55092 and 10218 gene has been introduced or disrupted. The invention still further provides isolated 27875, 22025, 27420, 17906, 16319, 55092 or 10218 proteins, fusion proteins, antigenic peptides and anti-27875, 22025, 27420, 17906, 16319, 55092 or 10218 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
Public/Granted literature
- US20040006016A1 Novel 27875, 22025 ,27420, 17906, 16319, 55092 and 10218 molecules and uses therefor Public/Granted day:2004-01-08
Information query
